Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Physiological StressDisorder of AgingSkin DiseasesWrinklesNasolabial Folds
Interventions
DEVICE

Hyaluronic Acid Filler

The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.

Trial Locations (1)

60311

Praxisklinik Kaiserplatz, Frankfurt am Main

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY

NCT01305187 - Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3 | Biotech Hunter | Biotech Hunter